Helen M. Thackray insider trades

Open-market stock purchases and sales by Helen M. Thackray, Chief R&D Officer at Biocryst Pharmaceuticals Inc, from SEC Form 4 filings since Jan 9, 2014.

Track record: 100% of 1 scored buy are up 5% or more since purchase, averaging +72%.

Recent trades

No open-market trades in the last 12 months.

Companies traded

  • BCRX Biocryst Pharmaceuticals Inc: 1 buy, 3 sales, last Mar 31, 2025
  • IMGN ImmunoGen, Inc: other filings, last Feb 12, 2024
  • GLYC Glycomimetics Inc: 10 sales, last Jan 20, 2021

Get free alerts when Helen M. Thackray files a new trade →